Skye Bioscience, Inc. — Director's Dealing 2021

Sep 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2021-09-14

Reporting Person: TYLE PRAVEEN (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-14	Director Stock Option (Right to Buy)	$0.12	A	25000	Acquired	2031-09-14	Common Stock (25000.0)	Direct

Footnotes

F1: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months.